{"pmid":32440857,"title":"Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China.","text":["Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China.","BACKGROUND: The clinical characteristics and disease course in COVID-19 patients with pre-existing decompensated cirrhosis has not been described so far. METHODS: In this case series, we report three patients with confirmed COVID-19 and pre-existing decompensated cirrhosis from three hospitals in Hubei, the epicenter of the outbreak in China. RESULT: Patient 1 was a 53-year-old man with hepatitis B virus-related cirrhosis, portal hypertension, and ascites. Though receiving intensive support, he died of irreversible multiple organ dysfunction syndrome 48 days after the onset of the illness. Patient 2 was a 75-year-old woman with a history of schistosomiasis-related cirrhosis, portal hypertension, and ascites. Her family members requested that invasive rescue measures not be undertaken, and she died of acute respiratory distress syndrome 40 days after presenting with COVID-19 infection. Patient 3 was an 87-year-old man with alcohol-related cirrhosis, portal hypertension, and esophageal variceal hemorrhage. He was discharged from the hospital 29 days after illness onset. CONCLUSION: The case series raise the possibility that decompensated cirrhosis may be a risk factor for a poor outcome in patients with COVID-19.","Hepatol Int","Qi, Xiaolong","Wang, Jitao","Li, Xinyu","Wang, Zhengyan","Liu, Yanna","Yang, Hua","Li, Xiaodan","Shi, Jindong","Xiang, Huihua","Liu, Tao","Kawada, Norifumi","Maruyama, Hitoshi","Jiang, Zicheng","Wang, Fengmei","Takehara, Tetsuo","Rockey, Don C","Sarin, Shiv Kumar","32440857"],"abstract":["BACKGROUND: The clinical characteristics and disease course in COVID-19 patients with pre-existing decompensated cirrhosis has not been described so far. METHODS: In this case series, we report three patients with confirmed COVID-19 and pre-existing decompensated cirrhosis from three hospitals in Hubei, the epicenter of the outbreak in China. RESULT: Patient 1 was a 53-year-old man with hepatitis B virus-related cirrhosis, portal hypertension, and ascites. Though receiving intensive support, he died of irreversible multiple organ dysfunction syndrome 48 days after the onset of the illness. Patient 2 was a 75-year-old woman with a history of schistosomiasis-related cirrhosis, portal hypertension, and ascites. Her family members requested that invasive rescue measures not be undertaken, and she died of acute respiratory distress syndrome 40 days after presenting with COVID-19 infection. Patient 3 was an 87-year-old man with alcohol-related cirrhosis, portal hypertension, and esophageal variceal hemorrhage. He was discharged from the hospital 29 days after illness onset. CONCLUSION: The case series raise the possibility that decompensated cirrhosis may be a risk factor for a poor outcome in patients with COVID-19."],"journal":"Hepatol Int","authors":["Qi, Xiaolong","Wang, Jitao","Li, Xinyu","Wang, Zhengyan","Liu, Yanna","Yang, Hua","Li, Xiaodan","Shi, Jindong","Xiang, Huihua","Liu, Tao","Kawada, Norifumi","Maruyama, Hitoshi","Jiang, Zicheng","Wang, Fengmei","Takehara, Tetsuo","Rockey, Don C","Sarin, Shiv Kumar"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32440857","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s12072-020-10051-z","keywords":["advanced chronic liver disease","covid-19","clinical characteristics"],"locations":["Hubei","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Alcohols"],"topics":["Case Report"],"weight":1,"_version_":1667523504831987712,"score":9.490897,"similar":[{"pmid":32489751,"pmcid":"PMC7255538","title":"Managing Acute Portal Hypertensive Gastropathy Bleed During the Time of COVID-19 Pandemic: Novelty or Necessity?","text":["Managing Acute Portal Hypertensive Gastropathy Bleed During the Time of COVID-19 Pandemic: Novelty or Necessity?","Acute bleeding from portal hypertensive gastropathy (PHG) is an extremely rare event in the natural history of cirrhosis. The treatment recommendations include portal pressure reduction strategies including pharmacotherapy with vasoactive agents and beta-blockers and interventional strategies such as transjugular intrahepatic portosystemic shunt placement. In this report, we present the case of a patient with cirrhosis in whom acute PHG-related bleed was managed with endoscopic band ligation, a therapeutic modality which has not been described in current literature. Our decision to re-purpose a technique for variceal bleeding stems from the fact that during the ongoing COVID-19 pandemic, the technical assistance, resource availability, and sourcing of materials that were required for us to follow recommended management guidelines for acute PHG-related bleed was severely affected due to imposed lockdown between districts and states.","Cureus","Philips, Cyriac A","Kumbar, Sandeep","Ahamed, Rizwan","Augustine, Philip","32489751"],"abstract":["Acute bleeding from portal hypertensive gastropathy (PHG) is an extremely rare event in the natural history of cirrhosis. The treatment recommendations include portal pressure reduction strategies including pharmacotherapy with vasoactive agents and beta-blockers and interventional strategies such as transjugular intrahepatic portosystemic shunt placement. In this report, we present the case of a patient with cirrhosis in whom acute PHG-related bleed was managed with endoscopic band ligation, a therapeutic modality which has not been described in current literature. Our decision to re-purpose a technique for variceal bleeding stems from the fact that during the ongoing COVID-19 pandemic, the technical assistance, resource availability, and sourcing of materials that were required for us to follow recommended management guidelines for acute PHG-related bleed was severely affected due to imposed lockdown between districts and states."],"journal":"Cureus","authors":["Philips, Cyriac A","Kumbar, Sandeep","Ahamed, Rizwan","Augustine, Philip"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489751","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.7759/cureus.8333","keywords":["banding","cirrhosis","coronavirus","covid","endoscopy","evl","gi bleeding","phg"],"topics":["Prevention"],"weight":1,"_version_":1668623433709125633,"score":338.6298},{"pmid":32369658,"title":"Acute on Chronic Liver Failure from Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","text":["Acute on Chronic Liver Failure from Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious viral disease that predominantly causes respiratory symptoms. Elevated liver enzymes have been reported during the course of disease and appear to be common. We present a 56-yearold woman with a history of decompensated alcoholic cirrhosis who presented with abdominal pain, fever and diarrhea and was found to have acute on chronic liver failure secondary to SARS-CoV-2 infection. The patient was treated with empiric antibiotic and supportive care with subsequent improvement.","Liver Int","Qiu, He","Wander, Praneet","Bernstein, David","Satapathy, Sanjaya K","32369658"],"abstract":["The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious viral disease that predominantly causes respiratory symptoms. Elevated liver enzymes have been reported during the course of disease and appear to be common. We present a 56-yearold woman with a history of decompensated alcoholic cirrhosis who presented with abdominal pain, fever and diarrhea and was found to have acute on chronic liver failure secondary to SARS-CoV-2 infection. The patient was treated with empiric antibiotic and supportive care with subsequent improvement."],"journal":"Liver Int","authors":["Qiu, He","Wander, Praneet","Bernstein, David","Satapathy, Sanjaya K"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369658","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/liv.14506","keywords":["acute on chronic liver failure","covid-19","sars-cov-2"],"topics":["Case Report"],"weight":1,"_version_":1666138496209780736,"score":240.08034},{"pmid":32251003,"title":"Lung transplantation as therapeutic option in acute respiratory distress syndrome for COVID-19-related pulmonary fibrosis.","text":["Lung transplantation as therapeutic option in acute respiratory distress syndrome for COVID-19-related pulmonary fibrosis.","BACKGROUND: Critical patients with the 2019 coronavirus disease (COVID-19), even those whose nucleic acid test results had turned negative and those receiving maximal medical support, have been noted to progress to irreversible fatal respiratory failure. Lung transplantation (LT) as the sole therapy for end-stage pulmonary fibrosis related to acute respiratory distress syndrome has been considered as the ultimate rescue therapy for these patients. METHODS: From February 10 to March 10, 2020, three male patients were urgently assessed and listed for transplantation. After conducting a full ethical review and after obtaining assent from the family of the patients, we performed three LT procedures for COVID-19 patients with illness durations of >1 month and extremely high sequential organ failure assessment (SOFA) scores. RESULTS: Two of the three recipients survived post-LT and started participating in a rehabilitation program. Pearls of the LT team collaboration and perioperative logistics were summarized and continually improved. The pathological results of the explanted lungs were concordant with the critical clinical manifestation, and provided insight towards better understanding of the disease. Government health affair systems, virology detection tools, and modern communication technology all play key roles towards the survival of the patients and their rehabilitation. CONCLUSIONS: Lung transplantation can be performed in end-stage patients with respiratory failure due to COVID-19-related pulmonary fibrosis. If confirmed positive-turned-negative virology status without organ dysfunction, LT provided the final option for these patients to avoid certain death, with proper protection of transplant surgeons and medical staffs. By ensuring instant seamless care for both patients and medical teams, the goal of reducing the mortality rate and salvaging the lives of patients with COVID-19 can be attained.","Chin Med J (Engl)","Chen, Jing-Yu","Qiao, Kun","Liu, Feng","Wu, Bo","Xu, Xin","Jiao, Guo-Qing","Lu, Rong-Guo","Li, Hui-Xing","Zhao, Jin","Huang, Jian","Yang, Yi","Lu, Xiao-Jie","Li, Jia-Shu","Jiang, Shu-Yun","Wang, Da-Peng","Hu, Chun-Xiao","Wang, Gui-Long","Huang, Dong-Xiao","Jiao, Guo-Hui","Wei, Dong","Ye, Shu-Gao","Huang, Jian-An","Zhou, Li","Zhang, Xiao-Qin","He, Jian-Xing","32251003"],"abstract":["BACKGROUND: Critical patients with the 2019 coronavirus disease (COVID-19), even those whose nucleic acid test results had turned negative and those receiving maximal medical support, have been noted to progress to irreversible fatal respiratory failure. Lung transplantation (LT) as the sole therapy for end-stage pulmonary fibrosis related to acute respiratory distress syndrome has been considered as the ultimate rescue therapy for these patients. METHODS: From February 10 to March 10, 2020, three male patients were urgently assessed and listed for transplantation. After conducting a full ethical review and after obtaining assent from the family of the patients, we performed three LT procedures for COVID-19 patients with illness durations of >1 month and extremely high sequential organ failure assessment (SOFA) scores. RESULTS: Two of the three recipients survived post-LT and started participating in a rehabilitation program. Pearls of the LT team collaboration and perioperative logistics were summarized and continually improved. The pathological results of the explanted lungs were concordant with the critical clinical manifestation, and provided insight towards better understanding of the disease. Government health affair systems, virology detection tools, and modern communication technology all play key roles towards the survival of the patients and their rehabilitation. CONCLUSIONS: Lung transplantation can be performed in end-stage patients with respiratory failure due to COVID-19-related pulmonary fibrosis. If confirmed positive-turned-negative virology status without organ dysfunction, LT provided the final option for these patients to avoid certain death, with proper protection of transplant surgeons and medical staffs. By ensuring instant seamless care for both patients and medical teams, the goal of reducing the mortality rate and salvaging the lives of patients with COVID-19 can be attained."],"journal":"Chin Med J (Engl)","authors":["Chen, Jing-Yu","Qiao, Kun","Liu, Feng","Wu, Bo","Xu, Xin","Jiao, Guo-Qing","Lu, Rong-Guo","Li, Hui-Xing","Zhao, Jin","Huang, Jian","Yang, Yi","Lu, Xiao-Jie","Li, Jia-Shu","Jiang, Shu-Yun","Wang, Da-Peng","Hu, Chun-Xiao","Wang, Gui-Long","Huang, Dong-Xiao","Jiao, Guo-Hui","Wei, Dong","Ye, Shu-Gao","Huang, Jian-An","Zhou, Li","Zhang, Xiao-Qin","He, Jian-Xing"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251003","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1097/CM9.0000000000000839","topics":["Treatment","Prevention"],"weight":1,"_version_":1666138491003600897,"score":224.48586},{"pmid":32298769,"pmcid":"PMC7194911","title":"The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care.","text":["The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care.","The coronavirus disease 2019 (COVID-19) pandemic has shattered the meticulously developed processes by which we delivered quality care for patients with cirrhosis. Care has been transformed by the crisis, but enduring lessons have been learned. In this article, we review how COVID-19 will impact cirrhosis care. We describe how this impact unfolds over 3 waves; i) an intense period with prioritized high-acuity care with delayed elective procedures and routine care during physical distancing, ii) a challenging 'return to normal' following the end of physical distancing, with increased emergent decompensations, morbidity, and systems of care overwhelmed by the backlog of deferred care, and iii) a protracted period of suboptimal outcomes characterized by missed diagnoses, progressive disease and loss to follow-up. We outline the concrete steps required to preserve the quality of care provided to patients with cirrhosis. This includes an intensification of the preventative care provided to patients with compensated cirrhosis, proactive chronic disease management, robust telehealth programs, and a reorganization of care delivery to provide a full service of care with flexible clinical staffing. Managing the pandemic of a serious chronic disease in the midst of a global infectious pandemic is challenging. It is incumbent upon the entire healthcare establishment to be strong enough to weather the storm. Change is needed.","J Hepatol","Tapper, Elliot B","Asrani, Sumeet K","32298769"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic has shattered the meticulously developed processes by which we delivered quality care for patients with cirrhosis. Care has been transformed by the crisis, but enduring lessons have been learned. In this article, we review how COVID-19 will impact cirrhosis care. We describe how this impact unfolds over 3 waves; i) an intense period with prioritized high-acuity care with delayed elective procedures and routine care during physical distancing, ii) a challenging 'return to normal' following the end of physical distancing, with increased emergent decompensations, morbidity, and systems of care overwhelmed by the backlog of deferred care, and iii) a protracted period of suboptimal outcomes characterized by missed diagnoses, progressive disease and loss to follow-up. We outline the concrete steps required to preserve the quality of care provided to patients with cirrhosis. This includes an intensification of the preventative care provided to patients with compensated cirrhosis, proactive chronic disease management, robust telehealth programs, and a reorganization of care delivery to provide a full service of care with flexible clinical staffing. Managing the pandemic of a serious chronic disease in the midst of a global infectious pandemic is challenging. It is incumbent upon the entire healthcare establishment to be strong enough to weather the storm. Change is needed."],"journal":"J Hepatol","authors":["Tapper, Elliot B","Asrani, Sumeet K"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298769","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jhep.2020.04.005","keywords":["hepatic encephalopathy","hepatocellular carcinoma","liver disease","telemedicine","varices"],"topics":["Prevention"],"weight":1,"_version_":1666138493287399424,"score":207.73318},{"pmid":32174095,"title":"[Advances in the research of mechanism of pulmonary fibrosis induced by Corona Virus Disease 2019 and the corresponding therapeutic measures].","text":["[Advances in the research of mechanism of pulmonary fibrosis induced by Corona Virus Disease 2019 and the corresponding therapeutic measures].","The Corona Virus Disease 2019 (COVID-19) outbroke in Wuhan, China in December 2019 and the severe acute respiratory syndrome (SARS) outbroke in Guangzhou, China in 2003 were caused by highly pathogenic coronaviruses with high homology. Since the 2019 novel coronavirus has strong transmissibility and progress rapidly. It has caused negative social effects and massive economic damage on a global scale. While there is currently no vaccine or effective drugs. Pulmonary fibrosis is a pulmonary disease with progressive fibrosis, which is the main factor leading to pulmonary dysfunction and quality of life decline in SARS survivors after recovery. Extensive epidemiological, viral immunological, and current clinical evidences support the possibility that pulmonary fibrosis may be one of the major complications in COVID-19 patients. Although there are no reports on the mechanism of COVID-19 inducing pulmonary fibrosis, based on the existing theoretical basis, we focus on the possible mechanism of COVID-19 sustained lung damaging, the key role of abnormal immune mechanism in the initiation and promotion of pulmonary fibrosis, and the corresponding therapeutic measures.","Zhonghua Shao Shang Za Zhi","Wang, J","Wang, B J","Yang, J C","Wang, M Y","Chen, C","Luo, G X","He, W F","32174095"],"abstract":["The Corona Virus Disease 2019 (COVID-19) outbroke in Wuhan, China in December 2019 and the severe acute respiratory syndrome (SARS) outbroke in Guangzhou, China in 2003 were caused by highly pathogenic coronaviruses with high homology. Since the 2019 novel coronavirus has strong transmissibility and progress rapidly. It has caused negative social effects and massive economic damage on a global scale. While there is currently no vaccine or effective drugs. Pulmonary fibrosis is a pulmonary disease with progressive fibrosis, which is the main factor leading to pulmonary dysfunction and quality of life decline in SARS survivors after recovery. Extensive epidemiological, viral immunological, and current clinical evidences support the possibility that pulmonary fibrosis may be one of the major complications in COVID-19 patients. Although there are no reports on the mechanism of COVID-19 inducing pulmonary fibrosis, based on the existing theoretical basis, we focus on the possible mechanism of COVID-19 sustained lung damaging, the key role of abnormal immune mechanism in the initiation and promotion of pulmonary fibrosis, and the corresponding therapeutic measures."],"journal":"Zhonghua Shao Shang Za Zhi","authors":["Wang, J","Wang, B J","Yang, J C","Wang, M Y","Chen, C","Luo, G X","He, W F"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32174095","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.3760/cma.j.cn501120-20200307-00132","keywords":["acute respiratory distress syndrome","corona virus disease 2019","cytokines","immune system","pulmonary fibrosis"],"locations":["Wuhan","China","Guangzhou","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1666138490600947712,"score":202.95946}]}